FCF Biotech Venture Capital Monitor - USA 11/2022 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of  November 2022, we identify the following current VC trends in the US-Biotech sector:

• In 2022, overall Biotech funding in the USA has reached USD 28,472m so far
• The top 5 deals exceed USD 340m each, largest transaction amounted to USD 3,000m in Altos Labs
• ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by 8VC (USA) and RA Capital Management (USA)
• Oncology still dominates as the top indication

To access the full report, please click here.